Anti-arrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: The importance of optimal beta-blocker dose titration

Int J Cardiol. 2021 Sep 1:338:150-151. doi: 10.1016/j.ijcard.2021.06.009. Epub 2021 Jun 15.

Authors

Alessio Gasperetti¹, Mattia Targetti², Iacopo Olivotto³

Affiliations

¹ Cardiology Department, Johns Hopkins University, Baltimore, MD, USA.
² Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy.
³ Cardiomyopathy Unit, Careggi University Hospital, Florence, Italy. Electronic address: iacopo.olivotto@unifi.it.

PMID: 34139230
DOI: 10.1016/j.ijcard.2021.06.009

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Arrhythmia Agents / therapeutic use
Arrhythmogenic Right Ventricular Dysplasia* / diagnosis
Arrhythmogenic Right Ventricular Dysplasia* / drug therapy
Death, Sudden, Cardiac
Electrocardiography
Humans
Pharmaceutical Preparations*

Substances

Anti-Arrhythmia Agents
Pharmaceutical Preparations